Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 09:43AM ET
14.46
Dollar change
-0.50
Percentage change
-3.34
%
IndexRUT P/E- EPS (ttm)-0.15 Insider Own6.21% Shs Outstand62.07M Perf Week-6.04%
Market Cap902.74M Forward P/E- EPS next Y-1.87 Insider Trans-2.32% Shs Float58.56M Perf Month-15.88%
Income-9.06M PEG- EPS next Q-0.62 Inst Own95.43% Short Float9.57% Perf Quarter45.18%
Sales58.75M P/S15.37 EPS this Y-1599.84% Inst Trans-8.40% Short Ratio4.04 Perf Half Y207.01%
Book/sh2.46 P/B5.88 EPS next Y26.60% ROA-3.04% Short Interest5.60M Perf Year117.44%
Cash/sh3.68 P/C3.93 EPS next 5Y- ROE-6.15% 52W Range4.29 - 21.88 Perf YTD50.31%
Dividend Est.- P/FCF- EPS past 5Y48.88% ROI-4.95% 52W High-33.91% Beta2.08
Dividend TTM- Quick Ratio4.46 Sales past 5Y15.77% Gross Margin69.59% 52W Low237.06% ATR (14)1.09
Dividend Ex-Date- Current Ratio4.48 EPS Y/Y TTM92.56% Oper. Margin-286.38% RSI (14)38.85 Volatility4.96% 7.42%
Employees339 Debt/Eq0.22 Sales Y/Y TTM-61.33% Profit Margin-15.42% Recom1.45 Target Price24.78
Option/ShortYes / Yes LT Debt/Eq0.20 EPS Q/Q-457.69% Payout- Rel Volume0.24 Prev Close14.96
Sales Surprise-67.15% EPS Surprise-382.08% Sales Q/Q-85.33% EarningsMar 07 AMC Avg Volume1.39M Price14.46
SMA20-15.16% SMA50-10.06% SMA20066.62% Trades Volume26,663 Change-3.34%
Date Action Analyst Rating Change Price Target Change
Mar-04-24Reiterated BTIG Research Buy $12 → $24
Feb-14-24Downgrade H.C. Wainwright Buy → Neutral $12 → $14
Dec-20-23Upgrade Citigroup Neutral → Buy $7 → $13
Nov-07-23Upgrade Guggenheim Neutral → Buy $12
Mar-17-23Downgrade Guggenheim Buy → Neutral
Nov-22-22Downgrade Cowen Outperform → Market Perform
Nov-14-22Upgrade BMO Capital Markets Market Perform → Outperform $5.70 → $16
Jul-18-22Downgrade SMBC Nikko Outperform → Neutral $5
Jul-11-22Downgrade BMO Capital Markets Outperform → Market Perform $31 → $4
May-04-22Downgrade Guggenheim Buy → Neutral
Mar-14-24 08:18AM
Mar-09-24 01:09PM
Mar-08-24 07:19AM
12:30AM
Mar-07-24 10:42PM
09:55PM Loading…
09:55PM
05:30PM
04:01PM
Mar-06-24 11:29PM
Mar-01-24 05:48PM
Feb-29-24 10:00AM
Feb-27-24 05:45PM
Feb-02-24 04:30PM
07:19AM
Jan-15-24 04:51PM
04:30PM Loading…
Jan-08-24 04:30PM
Dec-17-23 12:03PM
Nov-07-23 10:56AM
08:59AM
01:15AM
Nov-06-23 05:12PM
04:27PM
04:01PM
Nov-02-23 04:30PM
Oct-31-23 04:30PM
Sep-05-23 07:00AM
Aug-31-23 04:30PM
Aug-19-23 07:40AM
Aug-14-23 11:19AM
Aug-11-23 01:26PM
12:33PM Loading…
Aug-10-23 12:33PM
07:01AM
Aug-09-23 11:30PM
05:50PM
04:52PM
04:01PM
Jul-31-23 05:35PM
Jul-05-23 11:55AM
Jun-28-23 08:12AM
Jun-08-23 07:27AM
May-14-23 08:09AM
May-10-23 12:10PM
12:30AM
May-09-23 05:25PM
04:21PM
04:01PM
May-05-23 08:27AM
May-04-23 04:30PM
Apr-25-23 10:01AM
Apr-24-23 06:15PM
Apr-07-23 08:48AM
Mar-22-23 01:22PM
Mar-20-23 06:59PM
Mar-18-23 02:52AM
Mar-17-23 06:15PM
Mar-16-23 12:17PM
07:10AM
Mar-15-23 11:00PM
05:35PM
04:01PM
Mar-14-23 12:32PM
08:00AM
Mar-11-23 07:30AM
Mar-09-23 03:59PM
Mar-08-23 05:36PM
Mar-07-23 06:00PM
Mar-02-23 04:30PM
Feb-20-23 09:56AM
Feb-17-23 06:27AM
Feb-14-23 10:01AM
Feb-13-23 05:20PM
Feb-06-23 04:30PM
Jan-24-23 07:57AM
06:48AM
Jan-06-23 06:15PM
Jan-04-23 05:50PM
04:30PM
Jan-02-23 09:57AM
Dec-29-22 06:51AM
Dec-06-22 08:01AM
04:48AM
Dec-05-22 09:55AM
Dec-02-22 09:35AM
Nov-29-22 12:57PM
Nov-22-22 11:55AM
Nov-18-22 02:54PM
10:15AM
08:39AM
Nov-17-22 06:10PM
09:55AM
Nov-14-22 06:31PM
Nov-09-22 05:31AM
Nov-07-22 06:40PM
03:02PM
Nov-04-22 06:51PM
Nov-03-22 11:30PM
06:05PM
04:01PM
Nov-02-22 04:30PM
Nov-01-22 09:55AM
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Peters Jeffrey StuartSenior VP and General CounselMar 06 '24Option Exercise10.9019,625213,87528,520Mar 08 04:14 PM
Peters Jeffrey StuartSenior VP and General CounselMar 06 '24Sale21.5019,625421,9388,895Mar 08 04:14 PM
Risser Eric BlasiusChief Operating OfficerMar 04 '24Option Exercise10.1515,000152,25080,059Mar 06 04:20 PM
Spitznagel ThomasSr VP, Technical OpsMar 04 '24Option Exercise11.5010,000115,00018,316Mar 06 04:19 PM
Risser Eric BlasiusChief Operating OfficerMar 04 '24Sale19.7641,159813,50138,900Mar 06 04:20 PM
Karrels JamesSVP, CFO and SecretaryMar 04 '24Sale20.5030,000615,000171,452Mar 06 04:18 PM
Spitznagel ThomasSr VP, Technical OpsMar 04 '24Sale20.0010,000200,0008,316Mar 06 04:19 PM
Peters Jeffrey StuartSenior VP and General CounselFeb 26 '24Sale17.2216,124277,6558,895Feb 28 04:20 PM
Peters Jeffrey StuartSenior VP and General CounselFeb 22 '24Option Exercise0.0026,250035,145Feb 26 04:27 PM
Bonvini EzioSr VP, Research & CSOFeb 22 '24Option Exercise0.0028,1250110,258Feb 26 04:26 PM
Bonvini EzioSr VP, Research & CSOFeb 15 '24Option Exercise0.0016,670088,004Feb 20 06:03 PM
Risser Eric BlasiusChief Operating OfficerFeb 15 '24Option Exercise0.0016,670070,938Feb 20 06:04 PM
Cilinski LynnVP, Controller and TreasurerFeb 15 '24Option Exercise0.006,66808,591Feb 20 06:04 PM
Koenig ScottPresident and CEOFeb 15 '24Option Exercise0.0042,34101,091,977Feb 20 06:04 PM
Peters Jeffrey StuartSenior VP and General CounselFeb 15 '24Option Exercise0.0013,336013,336Feb 20 06:05 PM
Spitznagel ThomasSr VP, Technical OpsFeb 15 '24Option Exercise0.0013,336013,336Feb 20 06:03 PM
Karrels JamesSVP, CFO and SecretaryFeb 15 '24Option Exercise0.0015,0030206,779Feb 20 06:04 PM
Eck Stephen L.Chief Medical OfficerFeb 15 '24Option Exercise0.0016,670016,670Feb 20 06:41 PM
Bonvini EzioSr VP, Research & CSOFeb 07 '24Sale18.003,33460,01271,334Feb 07 04:19 PM
Peters Jeffrey StuartSenior VP and General CounselFeb 05 '24Option Exercise11.1176,251847,35576,251Feb 07 04:17 PM
Peters Jeffrey StuartSenior VP and General CounselFeb 05 '24Sale16.5076,2511,258,1420Feb 07 04:17 PM
Bonvini EzioSr VP, Research & CSOFeb 01 '24Sale15.0013,316199,74074,668Feb 02 04:21 PM
Bonvini EzioSr VP, Research & CSOJan 19 '24Sale12.0013,316159,79287,984Jan 22 04:57 PM
Bonvini EzioSr VP, Research & CSODec 20 '23Sale10.0818,880190,310101,300Dec 21 04:12 PM
BIOTECH TARGET N V10% OwnerOct 02 '23Buy4.46150,000669,5859,929,963Oct 04 03:31 PM
BIOTECH TARGET N V10% OwnerSep 07 '23Buy5.26200,0001,052,8409,779,963Sep 11 03:39 PM
HURWITZ EDWARDDirectorAug 30 '23Buy4.9115,00073,65033,074Sep 01 04:06 PM